NYSE American - Nasdaq Real Time Price USD

Serina Therapeutics, Inc. (SER)

1.9400 +0.0500 (+2.65%)
At close: October 30 at 4:00:00 PM EDT
1.9500 +0.0100 (+0.52%)
After hours: October 30 at 7:23:23 PM EDT
Chart Range Bar
Loading chart for SER
  • Previous Close 1.8900
  • Open 1.4700
  • Bid 1.9200 x 10000
  • Ask 2.5000 x 10000
  • Day's Range 1.6926 - 2.5000
  • 52 Week Range 1.2200 - 4.9900
  • Volume 154,903
  • Avg. Volume 70,018
  • Market Cap (intraday) 49.277M
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) --
  • EPS (TTM) -1.8700
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 9.50

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

www.serinatx.com

16

Full Time Employees

December 31

Fiscal Year Ends

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SER
1.41%
S&P 500 (^GSPC)
10.73%

1-Year Return

SER
59.50%
S&P 500 (^GSPC)
11.11%

3-Year Return

SER
91.29%
S&P 500 (^GSPC)
81.91%

5-Year Return

SER
93.29%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -6.93M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-6M
-4M
-2M
0
-4000.0%
-3000.0%
-2000.0%
-1000.0%
0.0%
 

Analyst Insights

View More

Analyst Price Targets

8.00
9.50 Average
1.9400 Current
11.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/26/2026
Analyst BTIG
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 8 -> 8
 

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    49.28M

  • Enterprise Value

    29.46M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.63

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -92.30%

  • Return on Equity (ttm)

    -207.94%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -23.93M

  • Diluted EPS (ttm)

    -1.8700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    23.02M

  • Total Debt/Equity (mrq)

    20.04%

  • Levered Free Cash Flow (ttm)

    -12.35M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.9400 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch